Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: IOLCP

IOL Chemicals and Pharmaceuticals

Results filed 30 October 2026 · Market cap ₹5,215 crore · PE 24.6

GrowthGuidance raisedTranscript read

Revenue
+40.1%
on a year ago
EBITDA
+91.7%
on a year ago
Profit to shareholders
+117.1%
on a year ago
EBITDA margin
13.8%
+0.1 pts on last quarter

IOL Chemicals delivered 40.1% YoY revenue growth in Q2 FY27 to INR 795 crore, driven by a 70% growth in its non-ibuprofen portfolio and recovery in specialty chemicals. Operating margins expanded by over 300 bps YoY, leading management to raise FY27 revenue growth guidance to 25%+ with 14-15% EBITDA margins. However, strong PBT generation failed to convert into operational cash flows during H1 FY27 due to an INR 175 crore working capital outflow.

IOL Chemicals and Pharmaceuticals Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue795756+5.1%568+40.1%
Operating profit (EBIT)87.2282.15+6.2%37.09+135.2%
Operating margin11.0%10.9%+11 bps6.5%+444 bps
Other income5.518.18−32.6%6.88−19.9%
Exceptional items00–0–
Profit before exceptional items and tax87.2986.69+0.7%40.49+115.6%
Profit to shareholders65.0764.4+1.0%29.97+117.1%
Earnings per share (₹)2.212.20+0.5%1.02+116.7%

Source: IOL Chemicals and Pharmaceuticals Limited’s filing to NSE, 30 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

What stood out

  • Announced three major manufacturing projects with total planned investment of ~INR 495-500 crore funded through internal accruals
    SourceStrategic growth initiatives involving combined investment of approximately INR500 crores funded through internal accruals (Transcript, Original Page 4; Presentation, Original Page 10)
  • Strong growth in non-ibuprofen pharmaceutical API portfolio, rising to 45% of pharmaceutical revenue
    SourceNon-ibuprofen portfolio registered ~70% YoY revenue growth during Q2, contributing 45% of pharmaceutical revenue vs 38% in Q2 FY26 (Transcript, Original Page 3; Press Release, Original Page 3)
  • Chemicals business showed EBIT improvement to ~7% from ~1% YoY
    SourceChemicals EBIT contribution increased to approximately 7% during Q2 compared with around 1% in corresponding quarter last year (Transcript, Original Page 4; Press Release, Original Page 3)

Guidance

MetricGuidancePeriod
Revenue Growth
SourceAbhay Raj Singh: 'initially, we said that it will be around 15% to 20%... now overall terms, it will be 25% plus' (Transcript, Original Page 12, 19)
25%+ YoY growth for FY27 (revised upwards from initial 15-20%)FY27
EBITDA Margin
SourceTranscript, Original Page 11, 19; Presentation, Original Page 34
14% to 15%FY27
Capex
SourcePresentation, Original Page 34; Transcript, Original Page 10
INR 200 - 250 croreFY27
Exports Contribution
SourcePresentation, Original Page 34
25% to 30%FY27
Sustainable Long-Term EBITDA Margin
SourceTranscript, Original Page 13
15% to 17%FY29

Revenue guidance raised from 15%-20% to 25%+ for FY27 based on H1 performance visibility.

Tailwinds

  • Strong non-ibuprofen portfolio expansion
    SourceNon-ibuprofen API portfolio grew ~70% YoY in Q2, reaching 45% of pharma revenues vs 38% in Q2 FY26 (Transcript, Original Page 3)
  • High plant utilization across product segments
    SourceMajor products operating at 90% to 100% capacity utilization, with chemical plants (Ethyl Acetate, Acetic Anhydride) operating at 100% (Transcript, Original Pages 8, 11, 12)
  • Chemical segment turnaround and margin contribution
    SourceChemicals EBIT increased from INR 5.1 Cr (Q2 FY26) to INR 23.2 Cr (Q2 FY27), with EBIT contribution reaching ~7% (Presentation, Original Page 6; Transcript, Original Page 4)

Headwinds

  • Elevated other expenses due to power, fuel, and shipping freight
    SourceOther expenses increased to 14.5% of sales due to summer power/fuel costs and high ocean shipping freight (Transcript, Original Page 12)
  • Higher working capital requirements and finance costs
    SourceFinance costs increased to INR 5.4 crore from INR 3.5 crore YoY due to higher working capital utilization to support higher business volume (Transcript, Original Page 5)
  • Subdued operating cash flow relative to reported profit in H1
    SourceChanges in working capital absorbed INR 175.0 crore, resulting in H1 net operating cash flow of only INR 8.3 crore against PBT of INR 174.0 crore (Presentation, Original Page 9)

New businesses and products

capacity expansion · Equipment already ordered, construction underway at Barnala

Ibuprofen capacity expansion

Expected benefit
Capacity expands from 12,000 MTPA to 18,000 MTPA; 50% for merchant customers and 50% for captive formulation CDMO supply
Risks
Excess supply risk in ibuprofen market if global competitors or peers ramp up capacity
Timeline
Commissioning in Q3/Q4 FY28; full utilization in FY28-FY29
Investment
INR 350 crore
SourceTranscript, Original Page 4, 6, 9, 11; Presentation, Original Page 10

new business · Installed/Commissioned; validation batches given to anchor European customers; received Hungarian GMP compliance certificate

Pharmaceutical Formulations CDMO facility

Expected benefit
Forward integration for APIs with capacity of 1,500 Mn tablets/DC grade; expected asset turn ~1:1 with revenue of ~INR 125 crore at full run rate and higher margins than API
Risks
Customer regulatory approvals in respective European countries take 12-16 months
Timeline
Commercialization targeted in FY27/FY28
Investment
INR 110 crore
SourceTranscript, Original Pages 4, 7, 9, 10, 13, 16; Presentation, Original Page 10

partnership · Plant almost commissioned, starting test/validation batches in November 2026

Dedicated Specialty Chemicals facility under long-term tolling arrangement

Expected benefit
Cost-plus model toll manufacturing for a leading global chemical company, visibility on realization and profits, entry into chemical CDMO
Risks
Confidentiality restrictions; single customer dependency for the facility
Timeline
FY27 commissioning, ramp up starting end-November 2026
Investment
INR 35 crore
SourceTranscript, Original Pages 4, 16, 17; Presentation, Original Page 10

Things to check

  • Significant cash conversion lag in H1 FY27
    SourceStandalone net cash flow from operating activities was only INR 8.3 crore in H1 FY27 despite INR 174.0 crore PBT, heavily drained by INR 175.0 crore working capital changes (Presentation, Original Page 9)
  • Surge in short-term bank borrowings
    SourceShort-term borrowings increased from INR 132.0 crore in March 2026 to INR 194.2 crore as of September 2026 (Presentation, Original Page 8)

How the call went

Management provided a clear update on capex execution and broad strategic direction into CDMO and toll manufacturing, but repeatedly avoided sharing price vs volume realizations and individual product margin metrics.

Specific or vague
Reasonable on capex details, facility capacities, and company-level targets, but lacked specifics when asked for volume vs value splits and specific API pricing.
Candour
Management openly acknowledged that pricing remains market-driven and outside their control, and admitted inability to forecast ibuprofen pricing beyond 1-2 quarters.
The hard questions
Analysts probed on supply glut risks in ibuprofen, customer commitments for CDMO, working capital stretch, and commercialization timelines.

What analysts pressed on

  • Risk of capacity oversupply in global ibuprofen market
  • Timeline and customer ramp-up visibility for the newly installed CDMO formulations facility
  • Significant increase in working capital and borrowing requirements
  • Pass-through of surging raw material costs like acetic acid into paracetamol pricing

Answers that sidestepped

  • Did not share the volume versus value breakdown of revenue growth, stating the data was not handy (Transcript, Original Page 11, 15)
  • Refused to give pricing or per-kg realization trends for paracetamol or ibuprofen, citing customer confidentiality and regional variation (Transcript, Original Page 17, 18)
  • Declined to answer the impact of the European Stallion Group plant closure on acetyl/paracetamol pricing (Transcript, Original Page 19)

Numbers against the story

Management emphasized strong profit growth and operational leverage, highlighting that EBITDA grew ~80% YoY to INR 115 crore (reported as INR 109 crore in financials). However, cash flow from operations was severely depressed (INR 8.3 crore for H1 vs INR 129.5 crore PAT) due to an INR 175 crore working capital absorption and rise in receivables and inventories, which management framed merely as 'optimum utilization' of working capital limits.

Sources

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.